Other Issues

Enclosed for FDA review are final reports on 2-year carcinogenicity studies with topically applied benzoyl peroxide gels in F344 rats and B6C3F1 mice submitted by the Benzoyl Peroxide Study Group of CHPA.

CHPA charged IOM to develop a proposed framework for categorizing and prioritizing DS ingredients based on safety issues, describe a process for developing a system of scientific reviews for evaluating the safety of DS ingredients, and develop at least six scientific reviews as prototypes for the system.

Oral testimony of the Consumer Healthcare Products Association to the White House Commission on Complementary and Alternative Medicine Policy.

Letter to Charles Ganley, M.D. regarding the agency's determination and comments pertaining to psyllium.

CHPA submits these written comments in response to FDA’s notice in the Federal Register concerning “Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements.”

Enclosed for DA review is an "Update on Safety Studies with Benzoyl Peroxide" submitted by the NDMA Benzoyl Peroxide Study Group.

Request for agency exercise of enforcement discretion regarding the addition of new Warning language to Drug Facts labeling for Over-the-Counter benzocaine liquid/gel products indicated for relieving oral discomfort.